Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission

Related Clinical Trial
Combination Chemotherapy and Dasatinib in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia Decitabine as Maintenance Therapy After Standard Therapy in Treating Patients With Previously Untreated Acute Myeloid Leukemia Donor Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia in Remission S0432 Tipifarnib in Treating Older Patients With Acute Myeloid Leukemia Reduced Intensity Donor Peripheral Blood Stem Cell Transplant in Treating Patients With De Novo or Secondary Acute Myeloid Leukemia in Remission Combination Chemotherapy With or Without Valspodar in Treating Patients With Previously Untreated Acute Myeloid Leukemia Tipifarnib in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia Tipifarnib and Etoposide in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia Alvocidib, Cytarabine, and Mitoxantrone in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia Bortezomib, Daunorubicin, and Cytarabine in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia Vorinostat and Gemtuzumab Ozogamicin in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia Comparing Three Different Combination Chemotherapy Regimens in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia Tipifarnib and Etoposide in Treating Older Patients With Newly Diagnosed, Previously Untreated Acute Myeloid Leukemia Flavopiridol, Cytarabine, and Mitoxantrone in Treating Patients With Relapsed or Refractory Acute Leukemia AKT Inhibitor MK-2206 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia Early Discharge and Outpatients Care in Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia Previously Treated With Intensive Chemotherapy Bortezomib, Mitoxantrone, Etoposide, and Cytarabine in Relapsed or Refractory Acute Myeloid Leukemia Vorinostat, Azacitidine, and Gemtuzumab Ozogamicin for Older Patients With Relapsed or Refractory AML Trebananib With or Without Low-Dose Cytarabine in Treating Patients With Acute Myeloid Leukemia Cholecalciferol in Treating Patients With Acute Myeloid Leukemia Undergoing Intensive Induction Chemotherapy Alvocidib, Cytarabine, and Mitoxantrone Hydrochloride or Cytarabine and Daunorubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia Cyclosporine, Pravastatin Sodium, Etoposide, and Mitoxantrone Hydrochloride in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia Metformin+Cytarabine for the Treatment of Relapsed/Refractory AML Arsenic Trioxide in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia Sirolimus, Idarubicin, and Cytarabine in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia Lithium Carbonate and Tretinoin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia Ixazomib (MLN9708) in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia Omacetaxine Mepesuccinate, Cytarabine, and Decitabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia CPX-351 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Lenalidomide and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia Choline Magnesium Trisalicylate and Combination Chemotherapy in Treating Patients With Acute Myeloid Leukemia AML Therapy With Irradiated Allogeneic Cells Decitabine, Cytarabine, and Daunorubicin Hydrochloride in Treating Patients With Acute Myeloid Leukemia Busulfan, Fludarabine Phosphate, and Anti-Thymocyte Globulin Followed By Donor Stem Cell Transplant and Azacitidine in Treating Patients With High-Risk Myelodysplastic Syndrome and Older Patients With Acute Myeloid Leukemia Azacitidine and Gemtuzumab Ozogamicin in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission Genetic and Molecular Characteristics of Mexican Adults With Acute Myeloid Leukemia: a Prospective Multicentric Study. Cytarabine With or Without SCH 900776 in Treating Adult Patients With Relapsed Acute Myeloid Leukemia Tipifarnib in Treating Older Patients With Acute Myeloid Leukemia Studying Biomarkers in Samples From Younger Patients With Acute Myeloid Leukemia Central Nervous System (CNS) Involvement in Acute Myeloid Leukemia (AML)

Brief Title

Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission

Official Title

A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients Over Age 60 in First Remission

Brief Summary

      This randomized phase III trial studies tipifarnib in treating patients with acute myeloid
      leukemia (AML) in remission. Tipifarnib may stop the growth of cancer cells by blocking the
      enzymes necessary for their growth. It is not yet known whether tipifarnib is more effective
      than observation alone in preventing the recurrence of AML.
    

Detailed Description

      PRIMARY OBJECTIVES:

      I. To compare R115777 (tipifarnib) maintenance therapy to observation only with respect to
      disease-free survival (DFS) in patients with AML in second or subsequent complete remission
      or in complete response (CR) following primary induction failure.

      SECONDARY OBJECTIVES:

      I. To compare overall survival of patients in both arms. II. To evaluate the long-term safety
      and toxicity of extended administration of R115777 in AML patients in remission.

      OUTLINE: Patients are randomized to 1 of 2 treatment arms.

      ARM A: Patients receive tipifarnib orally (PO) twice daily (BID) on days 1-21. Courses repeat
      every 28 days in the absence of disease progression or unacceptable toxicity.

      ARM B: Patients undergo observation only.

      After completion of study treatment, patients are followed up for 5 years.
    

Study Phase

Phase 3

Study Type

Interventional


Primary Outcome

Disease-free Survival

Secondary Outcome

 Overall Survival

Condition

Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome

Intervention

Clinical Observation

Study Arms / Comparison Groups

 Arm A (tipifarnib)
Description:  Patients receive tipifarnib PO BID on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.

Publications

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information


Recruitment Status

Procedure

Estimated Enrollment

144

Start Date

August 18, 2004


Primary Completion Date

February 20, 2015

Eligibility Criteria

        Inclusion Criteria:

          -  Patients eligible to enter this study must fall into one of these categories:

               -  Patients in first remission following primary induction failure

               -  Patients must have received at least two chemotherapy induction regimens

               -  Patients in second or subsequent remission

               -  Patients > 60 years old in first remission

          -  Patients must be in complete remission (CR) or morphologic remission (MR) by blood
             counts and bone marrow studies to enter the study

               -  Confirmatory bone marrow must be performed =< 2 weeks prior to randomization

          -  Patients must have morphologic proof (from bone marrow aspirate, smears or touch preps
             of marrow biopsy) that they had AML of one of the following types prior to achievement
             of CR/MR

               -  Acute myeloblastic leukemia, minimal differentiation (French-American-British
                  [FAB] M0)

               -  Acute myeloblastic leukemia without differentiation (FAB M1)

               -  Acute myeloblastic leukemia with maturation (FAB M2)

               -  Acute myelomonocytic leukemia (FAB M4)

               -  Acute monocytic leukemia (FAB M5)

               -  Acute erythroleukemia (FAB M6)

               -  Acute megakaryocytic leukemia (FAB M7)

               -  Refractory anemia with excess blasts in transformation (RAEB-T)

               -  AML by World Health Organization (WHO) criteria

               -  Acute myeloid leukemia with multilineage dysplasia

          -  Patients with acute promyelocytic leukemia (FAB M3) are not eligible

          -  Patients must be registered within 60 days of completion of therapy for the current
             remission; patients are eligible if they meet any of the criteria below:

               -  Within 60 days of remission (CR or MR) by peripheral blood counts following
                  induction therapy or

               -  Within 60 days of discharge from the hospital following induction therapy or

               -  Within 60 days of discharge from the hospital following post-remission therapy or

               -  Within 60 days of recovery of blood counts following last dose of chemotherapy

          -  All of the patients below are eligible for study entry:

               -  Patients who have received consolidation therapy

               -  Patients who have not received any consolidation or post remission therapy

               -  Patients who have had an autologous stem cell transplant

          -  Patients who have received an allogeneic transplant (bone marrow transplant [BMT] or
             peripheral stem cell transplant [PSCT]) in their current remission are ineligible;
             patients who have had an allogeneic transplant in a previous remission and are
             currently in remission after subsequent relapse are eligible

          -  Patients with a history of extramedullary disease are eligible if they are in complete
             remission at the time of study entry and no longer requiring therapy for their
             extramedullary disease

          -  Patients must not be pregnant or breast-feeding; all females of childbearing potential
             must have a blood test or urine study < 2 weeks prior to randomization to rule out
             pregnancy

          -  Women of childbearing potential and sexually active males are strongly advised to use
             an accepted and effective method of contraception

          -  Patients must not be known to have an allergy to imidazole drugs, such as clotrimazole
             ketoconazole, miconazole, econazole, or terconazole; this does not include
             fluconazole, voriconazole, or itraconazole

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 - 2

          -  Patients must not have active cardiac or pulmonary disease; but patient will be
             eligible if disease is medically controlled

          -  Patients must not have active renal disease; creatinine must be =< 1.5 x upper limit
             of normal

          -  Patients must not have active hepatic disease; total or direct bilirubin must be < 2
             mg/dl

          -  Serum glutamic oxaloacetic transaminase (SGOT) (aspartate aminotransferase [AST]) and
             serum glutamate pyruvate transaminase (SGPT) (alanine aminotransferase [ALT]) must be
             =< 2.5 times the upper limit of normal

          -  Absolute neutrophil count (ANC) >= 1000/mm^3

          -  Platelet count >= 50,000/mm^3

          -  Patients must not be taking a hepatic enzyme-inducing anti-convulsant; a patient will
             not be eligible for the study if the patient is currently taking one of these agents
             and cannot be switched to a non-hepatic enzyme-inducing anti-convulsant
      

Gender

All

Ages

18 Years - N/A

Accepts Healthy Volunteers

No

Contacts

Selina Luger, , 

Location Countries

Israel

Location Countries

Israel

Administrative Informations


NCT ID

NCT00093470

Organization ID

NCI-2009-00535

Secondary IDs

NCI-2009-00535

Responsible Party

Sponsor

Study Sponsor

National Cancer Institute (NCI)


Study Sponsor

Selina Luger, Principal Investigator, ECOG-ACRIN Cancer Research Group


Verification Date

March 2018